These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 37244843)
1. Feasibility and safety of targeted axillary dissection guided by intraoperative ultrasound after neoadjuvant treatment. Siso C; Esgueva A; Rivero J; Morales C; Miranda I; Peg V; Gil-Moreno A; Espinosa-Bravo M; Rubio IT Eur J Surg Oncol; 2023 Oct; 49(10):106938. PubMed ID: 37244843 [TBL] [Abstract][Full Text] [Related]
2. Targeted axillary dissection reduces residual nodal disease in clinically node- positive breast cancer after neoadjuvant chemotherapy. Cabıoğlu N; Karanlık H; Yılmaz R; Emiroğlu S; Tükenmez M; Bademler S; Şimşek DH; Kantarcı TR; Yirgin İK; Bayram A; Dursun M World J Surg Oncol; 2024 Jul; 22(1):178. PubMed ID: 38971793 [TBL] [Abstract][Full Text] [Related]
3. Intraoperative Ultrasound-Guided Excision of Axillary Clip in Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Therapy (ILINA Trial) : A New Tool to Guide the Excision of the Clipped Node After Neoadjuvant Treatment. Siso C; de Torres J; Esgueva-Colmenarejo A; Espinosa-Bravo M; Rus N; Cordoba O; Rodriguez R; Peg V; Rubio IT Ann Surg Oncol; 2018 Mar; 25(3):784-791. PubMed ID: 29197044 [TBL] [Abstract][Full Text] [Related]
4. Initial experience with targeted axillary dissection after neoadjuvant therapy in breast cancer patients. Pinto CS; Peleteiro B; Pinto CA; Osório F; Costa S; Magalhães A; Mora H; Amaral J; Gonçalves D; Fougo JL Breast Cancer; 2022 Jul; 29(4):709-719. PubMed ID: 35304711 [TBL] [Abstract][Full Text] [Related]
5. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. Caudle AS; Yang WT; Krishnamurthy S; Mittendorf EA; Black DM; Gilcrease MZ; Bedrosian I; Hobbs BP; DeSnyder SM; Hwang RF; Adrada BE; Shaitelman SF; Chavez-MacGregor M; Smith BD; Candelaria RP; Babiera GV; Dogan BE; Santiago L; Hunt KK; Kuerer HM J Clin Oncol; 2016 Apr; 34(10):1072-8. PubMed ID: 26811528 [TBL] [Abstract][Full Text] [Related]
6. False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy. de Boniface J; Frisell J; Kühn T; Wiklander-Bråkenhielm I; Dembrower K; Nyman P; Zouzos A; Gerber B; Reimer T; Hartmann S Breast Cancer Res Treat; 2022 Jun; 193(3):589-595. PubMed ID: 35451733 [TBL] [Abstract][Full Text] [Related]
7. Feasibility and validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Definitive results. Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL Surg Oncol; 2021 Sep; 38():101636. PubMed ID: 34303211 [TBL] [Abstract][Full Text] [Related]
8. Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer. Aragón-Sánchez S; Ciruelos-Gil E; López-Marín L; Galindo A; Tabuenca-Mateos MJ; Jiménez-Arranz S; Colmenero-Hernández M; Oliver-Pérez MR Surg Oncol; 2022 Sep; 44():101823. PubMed ID: 36041377 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of traditional targeted axillary dissection eligibility criteria for node-positive breast cancer after neoadjuvant chemotherapy in a prospective multicenter registry. Loveland-Jones C; Gaughan J; Caudle A; Murphy B; Samiian L; Byrum S; Brill K; Germaine P; Zhang X; Yoon-Flannery K; Carter T; Lopez A; Gruner R; Fantazzio M; Kuerer H Eur J Surg Oncol; 2024 Apr; 50(4):108245. PubMed ID: 38484493 [TBL] [Abstract][Full Text] [Related]
10. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study. Wu SY; Li JW; Wang YJ; Jin KR; Yang BL; Li JJ; Yu XL; Mo M; Hu N; Shao ZM; Liu GY Int J Surg; 2023 Jul; 109(7):1863-1870. PubMed ID: 37132193 [TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of de-escalated surgical procedure in axilla for node-positive breast cancer patients treated with neoadjuvant systemic therapy: A systematic review and meta-analysis. Song YX; Xu Z; Liang MX; Liu Z; Hou JC; Chen X; Xu D; Fei YJ; Tang JH Cancer Med; 2022 Nov; 11(22):4085-4103. PubMed ID: 35502768 [TBL] [Abstract][Full Text] [Related]
12. Accuracy and Limitations of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes. Aragon-Sanchez S; Oliver-Perez MR; Madariaga A; Tabuenca MJ; Martinez M; Galindo A; Arroyo ML; Gallego M; Blanco M; Ciruelos-Gil EM Breast J; 2022; 2022():1507881. PubMed ID: 36051467 [TBL] [Abstract][Full Text] [Related]
13. Prospective Evaluation of Radar-Localized Reflector-Directed Targeted Axillary Dissection in Node-Positive Breast Cancer Patients after Neoadjuvant Systemic Therapy. Gallagher KK; Iles K; Kuzmiak C; Louie R; McGuire KP; Ollila DW J Am Coll Surg; 2022 Apr; 234(4):538-545. PubMed ID: 35290273 [TBL] [Abstract][Full Text] [Related]
14. Carbon nanoparticles localized clipped node dissection combined with sentinel lymph node biopsy with indocyanine green and methylene blue after neoadjuvant therapy in node positive breast cancer in China: initial results of a prospective study. Yang X; Li Y; Ren XT; Fan L; Hua B World J Surg Oncol; 2023 Jul; 21(1):214. PubMed ID: 37480099 [TBL] [Abstract][Full Text] [Related]
15. Implementation of the Targeted Axillary Dissection Procedure in Clinically Node-Positive Breast Cancer: A Retrospective Analysis. Nijveldt JJ; Rajan KK; Boersma K; Noorda EM; van der Starre-Gaal J; Kate MV'V; Roeloffzen EMA; Vendel BN; Beek MA; Francken AB Ann Surg Oncol; 2024 Jul; 31(7):4477-4486. PubMed ID: 38523225 [TBL] [Abstract][Full Text] [Related]
16. Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer. Kuemmel S; Heil J; Bruzas S; Breit E; Schindowski D; Harrach H; Chiari O; Hellerhoff K; Bensmann E; Hanf V; Graßhoff ST; Deuschle P; Belke K; Polata S; Paepke S; Warm M; Meiler J; Schindlbeck C; Ruhwedel W; Beckmann U; Groh U; Dall P; Blohmer JU; Traut A; Reinisch M JAMA Surg; 2023 Aug; 158(8):807-815. PubMed ID: 37285140 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Axillary Lymph Node Marking with Magseed® before and after Neoadjuvant Systemic Therapy in Breast Cancer Patients: MAGNET Study. Martínez M; Jiménez S; Guzmán F; Fernández M; Arizaga E; Sanz C Breast J; 2022; 2022():6111907. PubMed ID: 35855102 [TBL] [Abstract][Full Text] [Related]
18. Targeted axillary dissection using Radioguided Occult Lesion Localization technique in the clinically negative marked lymph node after neoadjuvant treatment in breast cancer patients. Del Castillo A; Gomez-Modet S; Mata JM; Tejedor L Eur J Surg Oncol; 2023 Jul; 49(7):1184-1188. PubMed ID: 36958951 [TBL] [Abstract][Full Text] [Related]
19. Would Removal of All Ultrasound Abnormal Metastatic Lymph Nodes Without Sentinel Lymph Node Biopsy Be Accurate in Patients with Breast Cancer with Neoadjuvant Chemotherapy? Lim GH; Gudi M; Teo SY; Ng RP; Yan Z; Lee YS; Allen JC; Leong LCH Oncologist; 2020 Nov; 25(11):e1621-e1627. PubMed ID: 32537791 [TBL] [Abstract][Full Text] [Related]
20. Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment. Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL Surg Oncol; 2021 Sep; 38():101629. PubMed ID: 34171793 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]